TEL: 044-952-0102

診断用放射性医薬品および造影剤の世界市場 - 成長、動向、予測

Diagnostic Radiopharmaceuticals & Contrast Media Market - Growth, Trends And Forecast (2020 - 2025)

発行 Mordor Intelligence LLP 商品コード 391409
出版日 ページ情報 英文 118 Pages
納期: 2-3営業日
本日の銀行送金レート: 1USD=109.11円で換算しております。
診断用放射性医薬品および造影剤の世界市場 - 成長、動向、予測 Diagnostic Radiopharmaceuticals & Contrast Media Market - Growth, Trends And Forecast (2020 - 2025)
出版日: 2020年03月01日 ページ情報: 英文 118 Pages



第1章 イントロダクション

  • 調査成果
  • 調査の前提条件
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概況
  • 市場成長要因
  • 市場の阻害要因
  • ファイブフォース分析
    • 買い手の交渉力
    • 供給企業の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係

第5章 市場セグメンテーション

  • 放射性医薬品別
    • イメージングモダリティ別
      • SPECT
      • PET
    • 用途別
      • 診断
      • 治療
  • 造影剤
    • 用途別
    • 処置別
    • 適応症別
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Bioclinica
    • Bio-Optronics Inc.
    • DATATRAK International Inc.
    • ERT Clinical
    • IBM Watson Health
    • Medidata Solutions Inc.
    • MedNet Solutions Inc.
    • Oracle Corporation
    • Parexel International Corporation
    • ArisGlobal

第7章 市場機会および将来動向

Product Code: 53338

The global diagnostic radiopharmaceuticals and contrast media market is growing at a steady rate, due to factors, such as technological developments, increasing diagnostic applications in various diseases, government support, and rising cases of chronic diseases. Also, factors, such as shorter half-life of radiopharmaceuticals, stringent regulatory framework, and high capital investment, are expected to hinder the market growth.

The development in the minimally invasive therapeutic procedures has encouraged the usage of imaging equipment. This increase in the demand for image guidance has propelled the market. Additionally, medical imaging has witnessed numerous advancements in recent times. The emerging technologies help in enhancing the resolution and quality of the medical images, in turn, propelling the demand for contrast media and diagnostic radiopharmaceuticals. Rising cancer cost is another factor, which is impacting healthcare costs. The government is taking several initiatives for better cancer management. These initiatives are likely to affect the imaging industry, as they give the multinational companies a potential place to make significant investments.

Key Market Trends

Cardiology Sub-segment Captured the Largest Market Share and is Expected to Retain its Dominance

The major factor driving the growth of the market is the rising prevalence of cardiovascular diseases over the world. According to the estimates of the World Health Organization (WHO), in 2016, 17.9 million people died from CVDs. SPECT, which stands for single photon emission computed tomography, is a non-invasive procedure that can accurately identify areas of abnormal myocardial perfusion. It is also used to determine the functional capacity of the heart muscle and is able to separate living tissue from an irreversibly damaged tissue. This diagnostic procedure helps physicians find out if there are blockages in the coronary (heart) arteries, as well as to determine if the patient should undergo a coronary angiogram. In SPECT, cardiac-specific radiopharmaceuticals, such as 99mTc-tetrofosmin (Myoview, GE healthcare), 99mTc-sestamibi (Cardiolite, Bristol-Myers Squibb), or Thallium-201 chloride are administered. Hence, factors, such as the rising prevalence of cardiovascular diseases and technological advancements in the field of diagnostics, are expected to drive the growth of the market over the forecast period.

North America Captured the Largest Market Share and is Expected to Retain its Dominance

North America dominated the overall diagnostic radiopharmaceuticals and contrast media market, with the United States accounting for the major contributor to the market. The US diagnostic radiopharmaceuticals and contrast media market is anticipated to continue its expansion over the forecast period. The first gadolinium-based contrast agent was approved in the United States. Four agents were approved in the United States in the past decade, and they have set a string trend in the industry to continue to find more efficient, accurate, and safe agents.

The contrast media sales are expected to increase in the United States in the coming years. Among the different imaging modalities, sales of contrast media for the ultrasound market are likely to have a considerable growth rate. Diagnostic radioisotopes are a significant component of the US economy. Increase in chronic cardiac and neurological diseases is the primary driving factor for the market growth in the United States. Hence, the North American diagnostic radiopharmaceuticals and contrast media market is expected to retain its dominance over the forecast period.

Competitive Landscape

The presence of major market players, such as Bayer AG, GE Healthcare, Cardinal Health Inc., Nordion Inc., and Siemens Healthineers, is in turn, increasing the overall competitive rivalry of the market. The scarce presence of few companies operating in this sector, along with factors, such as powerful competitive strategy and strong market foothold, is resulting in the low score of the market, in terms of competitive rivalry.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents


  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Technology Advancements in Medical Imaging
    • 4.2.2 Increasing Demand for Image-guided Procedures and Diagnostics
    • 4.2.3 High Prevalence of Cancers and Cardiac Diseases
  • 4.3 Market Restraints
    • 4.3.1 High Costs of the Techniques- Not Easily Affordable
    • 4.3.2 Limited Health Insurance Coverage
    • 4.3.3 Short Half-life of Radiopharmaceuticals
  • 4.4 Industry Attractiveness Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 Radiopharmaceuticals
    • 5.1.1 By Type of Imaging Modality
      • SPECT
      • Tc-99
      • Tl-201
      • Ga-67
      • I-123
      • Other SPECTs
      • PET
      • F-18
      • Rb-82
      • Other PETs
    • 5.1.2 By Application
      • Diagnostic Application
      • SPECT Applications
      • Cardiology
      • Neurology
      • Thyroid
      • Other SPECT Applications
      • PET Application
      • Oncology
      • Cardiology
      • Neurology
      • Other PET Applications
      • Therapeutic Application
      • Thyroid
      • Lymphoma
      • Endocrine Tumors
      • Other Therapeutic Applications
  • 5.2 Contrast Media
    • 5.2.1 By Application
      • Ionizing Radiation-based Radioimaging
      • Non-Ionizing Radiation-based Radioimaging
    • 5.2.2 By Procedure
      • X-ray/Computed Tomography (CT)
      • Iodinated Contrast Media Ionic
      • Iodinated Contrast Media Non-Ionic
      • Barium-based Contrast Media
      • Magnetic Resonance Imaging (MRI)
      • Gadolinium-based Contrast Media
      • Other Magnetic Resonance Imaging
      • Ultrasound
    • 5.2.3 By Indication
      • Cardiovascular Disease
      • Oncology
      • Gastrointestinal
      • Disorders
      • Neurological
      • Disorders
      • Other Indications
  • 5.3 Geography
    • 5.3.1 North America
      • United States
      • Canada
      • Mexico
    • 5.3.2 Europe
      • United Kingdom
      • Germany
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.3.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.3.4 Middle East & Africa
      • GCC
      • South Africa
      • Rest of Middle East & Africa
    • 5.3.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 NTP Radioisotopes SOC Ltd
    • 6.1.2 Bayer AG
    • 6.1.3 Bracco Imaging S.p.A
    • 6.1.4 Curium
    • 6.1.5 GE Healthcare
    • 6.1.6 Guerbet Group
    • 6.1.7 Lantheus Holdings Inc
    • 6.1.8 Cardinal Health Inc.
    • 6.1.9 Nordion Inc.
    • 6.1.10 Siemens Healthineers